|1.||Bussone, Gennaro: 8 articles (05/2014 - 01/2002)|
|2.||Allais, Gianni: 7 articles (05/2014 - 06/2010)|
|3.||Benedetto, Chiara: 7 articles (05/2014 - 06/2010)|
|4.||Dodick, David W: 7 articles (02/2011 - 01/2004)|
|5.||Goadsby, P J: 7 articles (01/2007 - 05/2000)|
|6.||Omboni, Stefano: 6 articles (05/2014 - 06/2010)|
|7.||Tullo, Vincenzo: 6 articles (05/2014 - 06/2010)|
|8.||Rapoport, Alan M: 6 articles (09/2013 - 01/2004)|
|9.||Diener, H C: 6 articles (10/2008 - 02/2000)|
|10.||Pascual, J: 6 articles (01/2007 - 06/2000)|
|1.||Migraine Disorders (Migraine)
01/01/2005 - "Previous studies have demonstrated that orally administered formulations of zolmitriptan are rapidly and highly effective in the acute treatment of migraine. "
11/01/1997 - "Previous studies demonstrated that zolmitriptan at doses of 1 to 25 mg was highly effective in treating acute migraine attacks. "
01/01/2005 - "Oral zolmitriptan is highly effective in the acute treatment of migraine. "
01/01/2001 - "A stratified-care treatment strategy (including zolmitriptan as the representative of high-end therapy) is a highly cost-effective method of managing migraine in the primary care setting compared with stepped care, delivering improved clinical outcomes at no additional cost."
01/01/1999 - "In conclusion, 2.5 mg and 5 mg zolmitriptan are highly effective in treating both persistent and recurrent migraine headache."
10/01/2005 - "In phase one of the REALIZE study, zolmitriptan nasal spray demonstrated a significant headache response from 10 min post-dose and total symptom relief from 30 min post-dose. "
01/01/2006 - "There was no statistically significant improvement between zolmitriptan 10 mg (2 x 5 mg tablet) and placebo for the primary efficacy variable, headache response at 2 hours, nor any of the secondary variables tested. "
03/01/2002 - "Headache relief following zolmitriptan 2.5 mg (63%) was significantly greater than with placebo (22%) at 2 h post-dose (primary endpoint; P < 0.0001). "
06/01/1996 - "Plasma 311C90 concentrations were generally higher in those patients who responded to treatment with 311C90 in the plasma, but there was one patient with no quantifiable 311C90 in the plasma whose headache improved. "
11/01/1997 - "In patients with persistent or recurrent headache, a second zolmitriptan dose effectively treated both headache and nonheadache symptoms. "
11/01/2004 - "The efficacy of zolmitriptan was more pronounced in patients treating during the first 15 min following pain onset. "
08/01/2015 - "The size of the neurogenic flare (F = 10.9; p = 0.002) as well as electrically induced pain were significantly reduced by zolmitriptan (F = 4.46; p = 0.041). "
08/01/2015 - "Electrically induced neurogenic flare and pain was assessed after either placebo or zolmitriptan on the ventral thigh. "
01/01/2011 - "For zolmitriptan, 2-hour pain relief rates were higher in the good HTR subgroup (116/162, 72%) than in the intermediate (29/62, 47%) and poor/no use (44/111, 40%) HTR subgroups. "
10/01/2008 - "Significant pain reduction was seen only in the group receiving zolmitriptan nasal spray 5 mg with a mean visual analogue scale (VAS) score of 3.8 (s.d. "
|4.||Cluster Headache (Cluster Headaches)
01/01/2013 - "Although nasal spry of zolmitriptan is not available in Japan, it is also reported to be effective for the acute phase of cluster headache. "
07/01/2002 - "Oral zolmitriptan is also effective in the acute treatment of cluster headache. "
05/09/2000 - "Oral zolmitriptan is effective in the acute treatment of cluster headache."
10/01/2009 - "To conduct an individual subject meta-analysis of available controlled studies of zolmitriptan nasal spray in the acute treatment of cluster headache. "
10/01/2009 - "Zolmitriptan nasal spray in the acute treatment of cluster headache: a meta-analysis of two studies."
01/01/1996 - "The study also aimed to provide an initial safety profile for 311C90 when taken during the aura. "
01/01/2003 - "Zolmitriptan oral tablet is highly effective and well tolerated in the acute treatment of migraine with and without aura in adults. "
01/01/2003 - "In the pre-crossover phase, 1,093 patients aged 18-65 years with an established diagnosis of migraine with or without aura received intranasal zolmitriptan 5, 2.5, 1 or 0.5mg for the treatment of mild, moderate or severe migraine attacks. "
01/01/1999 - "In conclusion, zolmitriptan 2.5 mg and 5 mg show consistent effectiveness in the treatment of multiple migraine attacks in individual patients and are unaffected by gender, age and the presence of aura or the relationship to menses."
11/01/1997 - "Female and male patients, 12 to 65 years old, with migraine (with or without aura) for > or = 1 year, one to six migraines per month, and age at onset < 50 years were included; 327 patients were screened and randomized to receive either zolmitriptan (n = 219) or placebo (n = 108). "
|6.||Serotonin (5 Hydroxytryptamine)